JPRN-UMIN000014435
Completed
Phase 1
The feasibility of dendritic cell-based immunotherapy targeting synthesized long peptides containing helper epitopes for malignant tumor. - The feasibility of dendritic cell-based immunotherapy targeting synthesized long peptides for malignant tumor.
Medical Corporation Isokai Seren Clinic Tokyo0 sites10 target enrollmentJune 30, 2014
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Medical Corporation Isokai Seren Clinic Tokyo
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •The patients have been (1\) Diagnosed or suspected of myelodysplastic syndrome (MDS). (2\) Suspected of other severe clinical conditions or abnormal laboratory values. (3\) Diagnosed or suspected of a mental disorder or mental symptoms. (4\) Suspected of immunodeficiency and/or infection. Other exclusion criteria are as follows: (5\) Pregnant, lactating or suspected of pregnancy. (6\) Female patient rejecting to give consent to contraception during the therapy and for 70 days after the completion of the final administration. (7\) Taking in adrenocortical steroid (at the equivalent of 10mg predonine or prednisolone per day). (8\) Unsuitable for the therapy.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
DC for endometrial cancer patientsmetastatic endometrial cancerTherapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]EUCTR2018-004467-31-NL8
Completed
Phase 2
An exploratory study: Dendritic cells for immunotherapy of metastatic endometrial cancer patientsendometrial cancer10038594NL-OMON47953Radboud Universitair Medisch Centrum8
Completed
Not Applicable
Dendritic cell-based immunotherapy for ovrian cancer patients.NeoplasmsKCT0000831Asan Medical Center10
Not yet recruiting
Not Applicable
Dendritic cell-based immunotherapy combined with low-dose cyclophosphamide in patients with malignant pleural mesotheliomamesothelioma10035597NL-OMON32554Erasmus MC, Universitair Medisch Centrum Rotterdam10
Active, not recruiting
Phase 1
Dendritic cell-based immunotherapy for advanced solid tumours of children and young adultsChildren and young adults with advanced solid tumours: relapsed or metastatic sarcomas or central nervous system tumours.Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-003632-71-ESClínica Universidad de Navarra/Universidad de Navarra10